FDA reviewer: Teva's studies fail to support expanded Parkinson's use for Azilect

There is no demonstrated benefit of Teva's Azilect (rasagiline) for slowing the rate of progression of Parkinson's disease, a US FDA drug reviewer said, insisting that the company's data were "not robust" enough to support such a claim.

There is no demonstrated benefit of Teva's Azilect (rasagiline) for slowing the rate of progression of Parkinson's disease, a US FDA drug reviewer said, insisting that the company's data were "not robust" enough to support such a claim.

While Dr Leonard Kapcala, a clinical reviewer in the FDA's Division of Neurology Products, said he was deferring his final...

More from Neurological

Compass Pathways’ Antidepressant Advances In An Increasingly Tough Psychedelic Market

 
• By 

Psychedelics appear to be in vogue after years of being relegated to alternative medicine. But investor pushback after the highly anticipated release of Phase III trial data by Compass Pathways reveals an increasingly high bar for development.

Biogen’s Spinraza Follow-On May Offer Disease-Modifying Potential

 
• By 

Biogen hopes to move directly from Phase I to Phase III with salanersen, a higher-potency therapy that uses the same mechanism of action as Spinraza.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By 

Oral RNA splicing modulator has gone into a Phase II/III trial

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By 

Wales-based group launches with $140m series A.

More from Therapeutic Category

BioMarin’s Roctavian Continues to Shine In Hemophilia A Despite Commercial Woes

 

Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.

Novartis’s Cosentyx Suffers Rare Phase III Fail

 
• By 

Multi-blockbuster falls short in a giant cell arteritis study.

In Brief: 4DMT Fast-Tracks Long-Acting Wet AMD Therapy Trials, Cuts 25% Of Workforce

 

4D Molecular Therapeutics has fast-tracked its Phase III trials for 4D-150 in wet AMD, with top-line data from one now expected in H1 2027 and another underway ahead of schedule. The company is also cutting a quarter of its staff as it focuses on its late-stage pipeline and to help fund the trials.